|
1
|
Liu Y, Wang R, Hou J, Sun B, Zhu B, Qiao Z, Su Y, Zhu X. Paclitaxel/Chitosan Nanosupensions Provide Enhanced Intravesical Bladder Cancer Therapy with Sustained and Prolonged Delivery of Paclitaxel. ACS APPLIED BIO MATERIALS 2018; 1:1992-2001. [DOI: 10.1021/acsabm.8b00501] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Yongjia Liu
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Ruibin Wang
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Jingwen Hou
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Binbin Sun
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Bangshang Zhu
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
- State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Donghua University, 201620 Shanghai, China
| | - Zhiguang Qiao
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Yue Su
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| | - Xinyuan Zhu
- School of Chemistry and Chemical Engineering, Instrumental Analysis Center, Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedics, Ninth People’s Hospital, School of Medicine, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 200240 Shanghai, China
| |
Collapse
|
|
2
|
de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL. Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. Bladder Cancer 2018; 4:395-401. [PMID: 30417050 PMCID: PMC6218110 DOI: 10.3233/blc-180191] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Adjuvant intravesical instillations with bacillus Calmette-Guérin (BCG) is the recommended treatment option for patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC). Despite adequate BCG treatment, a large proportion of patients experience a recurrence. Although radical cystectomy is the gold standard for BCG unresponsive NMIBC, some patients are unfit or unwilling to consider this option. Objective: To assess the effectiveness of Hyperthermic IntraVEsical Chemotherapy (HIVEC®) in BCG unresponsive NMIBC patients. Methods: A post-hoc analysis was conducted of prospectively included intermediate-and high-risk NMIBC patients who were planned to receive HIVEC® treatment between October 2014 and November 2017. For the present analysis, only patients who met the BCG unresponsive definition were included. Patients were followed by cystoscopy and cytology every 3 months and a CT-urography scan yearly. The primary outcome was the disease-free survival (DFS). The Common Terminology Criteria for Adverse Events (CTCAE) was used to assess side-effects. Results: The study population consisted of 55 BCG unresponsive NMIBC patients of whom 52 underwent≥5 HIVEC® treatments. The median age and follow-up were 73 years and 14.0 months (IQR 7.6 – 24.6). The median DFS was 17.7 months (SE 6.72) and progression occurred in four patients. The 1-year cumulative incidence rate of disease recurrence/progression was 53%. Two patients experienced severe side-effects (CTCAE≥3). Conclusions: HIVEC® seems a valid treatment option for BCG unresponsive NMIBC patients. We report a median DFS of 17.7 months (SE 6.72), potentially avoiding or postponing the need for radical surgery in a proportion of these patients.
Collapse
Affiliation(s)
- Joep J de Jong
- Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Kees Hendricksen
- Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Marloes Rosier
- Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Hugh Mostafid
- Department of Urology, Royal Surrey County Hospital, Guildford, UK
| | - Joost L Boormans
- Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands
| |
Collapse
|
|
3
|
Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ. Factors Affecting Valrubicin Response in Patients with Bacillus Calmette-Guérin–Refractory Bladder Carcinoma in Situ. Postgrad Med 2015; 123:28-34. [DOI: 10.3810/pgm.2011.05.2281] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
|
4
|
Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol 2013; 31:1635-42. [DOI: 10.1016/j.urolonc.2012.04.010] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2012] [Revised: 04/10/2012] [Accepted: 04/10/2012] [Indexed: 10/28/2022]
|
|
6
|
Steinberg GD. Response to Lammers and Witjes article: new developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2011; 11:1331-2. [DOI: 10.1586/era.11.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|